+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genmab AS - logo

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.

From
From
Malignant Glioma - Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Glioma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Targeted Drug Delivery - Global Strategic Business Report - Product Thumbnail Image

Targeted Drug Delivery - Global Strategic Business Report

  • Report
  • June 2025
  • 168 Pages
  • Global
From
From
Immuno-Oncology - Thematic Intelligence - Product Thumbnail Image

Immuno-Oncology - Thematic Intelligence

  • Report
  • May 2023
  • 169 Pages
  • Global
From
Immuno-Oncology - Thematic Research - Product Thumbnail Image

Immuno-Oncology - Thematic Research

  • Report
  • May 2022
  • 167 Pages
  • Global
From
Antibody Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Antibody Therapeutics - Global Strategic Business Report

  • Report
  • June 2025
  • 577 Pages
  • Global
From
Antibody Discovery - Global Strategic Business Report - Product Thumbnail Image

Antibody Discovery - Global Strategic Business Report

  • Report
  • June 2025
  • 224 Pages
  • Global
From
Gastric Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Gastric Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 2657 Pages
  • Global
From
From
From
Pharmaceutical Market in Denmark 2025-2029 - Product Thumbnail Image

Pharmaceutical Market in Denmark 2025-2029

  • Report
  • March 2025
  • 186 Pages
  • Denmark
From
From
Factor II (Prothrombin) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Factor II (Prothrombin) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Pancreatic Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 4317 Pages
  • Global
From
Loading Indicator